Seegnal vs. Sano

An intuitive real-time user interface created for use at the point of care significantly improves the prevention of Drug-Related Problems (DRPs) tailored to individual patients. DRPs rank as the fourth leading cause of mortality in the United States, resulting in around 150,000 deaths annually and comprising 6-10% of all hospital admissions. Moreover, patients who are prescribed five or more medications face over a 20% likelihood of experiencing serious DRPs, which in turn contribute to billions of dollars in avoidable healthcare expenses. Each month, nearly 4.5 million individuals in the U.S. visit emergency rooms due to complications arising from DRPs. The platform features the most extensive data integration available, offering 50% more unique information and the ability to synchronize data from multiple sources. By leveraging AI and machine learning, it delivers real-time insights customized to each patient, incorporating factors such as lab results, estimated glomerular filtration rate (eGFR), genetic profiles, dietary habits, and usage of over-the-counter drugs. With a remarkable accuracy rate of 98% for both specificity and sensitivity, it significantly reduces alert fatigue by generating only 6% of the alerts typically issued by conventional systems. Additionally, the patented visualization technology employed at the point of care facilitates the swift detection, prioritization, and resolution of issues within a rapid timeframe of just 5 to 10 seconds, ensuring that patient care is both timely and effective. This cutting-edge methodology not only reduces the risks linked to DRPs but also promotes overall healthcare efficiency, ultimately leading to improved patient outcomes and satisfaction.

Sano Genetics offers an all-encompassing platform tailored for precision medicine and clinical trial initiatives, seamlessly merging elements such as patient recruitment, genetic analysis, informed consent, and continuous participant interaction to significantly optimize research workflows. This platform enables the development of customized protocols and the assembly of ethical submission materials, while also implementing digital prescreening and consent processes, as well as recruitment support through targeted online marketing, collaborations, and advocacy initiatives, thereby facilitating connections between sponsors, contract research organizations, and specific patient demographics that are frequently underserved in various areas. In addition, Sano provides accessible, non-invasive saliva-based DNA testing kits that present a cost-effective alternative to conventional blood draws, alongside logistical support for the collection and processing of samples. Their offerings extend to reliable genetic and biomarker evaluations from accredited labs, bioinformatics solutions, and the communication of results, enhanced by genetic counseling when appropriate, which collectively ensure a comprehensive approach to patient management and study integrity. Furthermore, by harnessing advanced technology and fostering community involvement, Sano Genetics is set to revolutionize the field of clinical trials and personalized healthcare, paving the way for more inclusive and efficient medical research. This innovative approach not only benefits sponsors but also prioritizes the needs of diverse patient populations.